

2nd Emirates Allergy & Clinical Immunology Conference

March 4 - 5, 2023
Beach Rotana Hotel, Abu Dhabi, UAE



DIAMOND SPONSORS



PLATINUM SPONSORS



GOLD SPONSOR



SILVER SPONSORS



SCIENTIFIC PARTNERS



www.gamt.ae



HAEi
HAE International

MANAGED BY:



www.eacic-uae.com

WELCOME MESSAGE

Dear Friends and Respected Colleagues,

On behalf of the organizing committee, I am delighted to welcome you to the **2nd Emirates Allergy and Clinical Immunology Conference**, endorsed by the Global Allergy and Asthma European Network (GA²LEN).

The programme is **accredited by DoH with 13 CME units** and will cover a broad range of topics such as respiratory allergy, skin allergy, urticaria and angioedema, inborn errors of the immune system, allergy testing, updates in allergy and clinical immunology for the practicing paediatricians, hot topics in dermatology for immunologists and allergists, together with the latest trends in allergy and clinical immunology.



Prof. Mohamed Abuzakouk, MD, PhD
Conference Chairman

Chair of the Scientific Committee



Dr. Hamad Al Hameli
Consultant in Allergy
Cleveland Clinic Abu Dhabi, UAE

Committee Members



Dr. Fulvio Salvo
Consultant in Allergy and Clinical Immunology,
Cleveland Clinic Abu Dhabi, UAE



Dr. Hiba Shendi
Consultant in Allergy and Clinical Immunology,
Tawam Hospital, Al Ain, UAE



Dr. Shuayb Elkhalfifa
Consultant in Allergy and Clinical Immunology,
Cleveland Clinic Abu Dhabi, UAE



Prof. Suleiman Al-Hammadi
Consultant in Allergy and Immunology
Dean of College of Medicine,
Mohammed Bin Rashid University of
Medicine and Health Sciences, Dubai, UAE



Dr. Inmaculada Cerecedo
Consultant in Allergy
Cleveland Clinic Abu Dhabi, UAE



Dr. Ravi Gutta
Consultant in Allergy and Immunology
Mediclinic Middle East, Dubai, UAE



Prof. Rand Arnaout
Consultant in Allergy and Clinical Immunology,
King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia



Prof. Andrew Gennery
Professor, Honorary Consultant
in Paediatric Immunology + HSCT
Newcastle upon Tyne, United Kingdom



Prof. Fares Zaitoun
Consultant in Allergy and Clinical Immunology,
Advanced Cure/Real Health Centres, Abu Dhabi, UAE

SPEAKERS



Prof. Mohamed Abuzakouk
Conference Chair
Consultant in Allergy & Clinical Immunology
Cleveland Clinic Abu Dhabi, UAE



Prof. Mona AlAhmad
Consultant in Internal Medicine,
Allergy & Clinical Immunology
Head of Al Rashed Allergy Centre,
Ministry of Health, Kuwait



Prof. Maryam Al-Nesf Al-Mansouri
Consultant in Allergy & Clinical Immunology
Adult Allergy and Applied Immunology
Fellowship Program Director
Hamad Medical Corporation, Qatar



Dr. Hiba Shendi
Consultant in Allergy and Clinical Immunology,
Tawam Hospital, Al Ain, UAE



Dr. Fulvio Salvo
Consultant in Allergy and Clinical Immunology,
Cleveland Clinic Abu Dhabi, UAE



Dr. Fadhel Al Sabbagh
Consultant in Allergy and Clinical Immunology,
Al Kindi Hospital, Bahrain



Dr. Shuayb Elkhalifa
Consultant in Allergy and Clinical Immunology,
Cleveland Clinic Abu Dhabi, UAE



Prof. Andrew Gennery
Honorary Consultant in Paediatric Immunology
and Haematopoietic Stem Cell Transplantation
Great North Children's Hospital,
Newcastle, United Kingdom



Prof. Fares Zaitoun
Consultant in Allergy and Clinical Immunology
Advanced Cure/Real Health Centres,
Abu Dhabi, UAE



Dr. Ravi Gutta
Consultant in Allergy and Immunology
Mediclinic Middle East, Dubai, UAE



Dr. Inmaculada Cerecedo
Consultant in Allergy
Cleveland Clinic Abu Dhabi, UAE



Dr. Stuart Carr
Consultant in Allergy and Immunology
Chief Medical Officer, Sno Clinic,
Abu Dhabi, UAE



Prof. Abdelouahab Bellou
Director of the Institute of Sciences in
Emergency Medicine
Academy of Medical Sciences,
Guangdong Provincial People Hospital
Guangzhou, China



Prof. Amer Azaz
Consultant in Pediatric Gastroenterology,
Hepatology and Nutrition
Sheikh Khalifa Medical City, Abu Dhabi, UAE



Prof. Suhail Al Amad
Professor and Consultant in Oral Medicine
University of Sharjah, UAE



Dr. Iman Nasr
Consultant in Internal Medicine, Immunology
and Allergy
Royal Hospital, Oman

SPEAKERS



Dr. Hamad Al Hameli
Consultant in Allergy
Cleveland Clinic Abu Dhabi, UAE



Dr. Fatima AlBreiki
Consultant in Dermatology
Chief of Dermatology Department
Ambulatory Healthcare Services,
Abu Dhabi, UAE



Prof. Salem Al Tamemi
Consultant in Allergy and Clinical Immunology,
Sultan Qaboos University, Muscat, Oman



Prof. Ahmed Aziz Bousfiha
Professor, Clinical Immunology Unit
Hassan II University, Casablanca, Morocco



Prof. Frank Siebenhaar
Head IFA Outpatient Clinic for Allergology
Charité – Berlin University of Medicine, Germany



Prof. Zaid Zoumot
Section Head, Pulmonology,
Respiratory Institute
Cleveland Clinic Abu Dhabi, UAE



Dr. Muna AlMurrawi
Consultant in Dermatology, Founder and CMO
Dr. Muna AlMurrawi Medical Center,
Abu Dhabi, UAE



Dr. Raghda AlMaashari
Consultant in Dermatology
Cleveland Clinic Abu Dhabi, UAE



Dr. Meera AlAdawi
Consultant in Dermatology
Sheikh Khalifa Medical City, Abu Dhabi, UAE



Dr. Said Isse
Consultant in Pulmonology
Cleveland Clinic Abu Dhabi, UAE



Ms. Lisa Timoner
Veterinary Advisor
Nestlé Purina PetCare - MENA



Dr. Muhammad Arif
Consultant in Pulmonology
Mediclinic Hospitals - Al Ain and
Al Jowhara, Abu Dhabi, UAE



Prof. Ian Pavord
Professor of Respiratory Medicine
Honorary Consultant Physician
Oxford University Hospital, United Kingdom



Dr. Abdulbaset Elkari
Consultant in Pulmonology
Tawam Hospital, Abu Dhabi, UAE



2nd Emirates Allergy & Clinical Immunology Conference

SCIENTIFIC AGENDA

DAY 1: Saturday, 4 March 2023

7:00 Onsite Registration

8:20 Welcome Note

Conference Chairman and Committee

8:30 **Keynote: The Global Burden of Allergy**

Prof. Mohamed Abuzakouk , UAE

Session 1: Respiratory Allergy Moderators: Dr. Fadhel Al Sabbagh & Prof. Irfan Shafiq

9:00 Taking it from the Top: Targeting a New Approach to Controlling Severe Asthma

Prof. Zaid Zoumot, UAE

9:20 Can Asthma Go Away?

Prof. Mona AlAhmad, Kuwait

9:40 Setting Ambitious Treatment Goals for Severe Asthma Patients
(Sponsored by GSK)

Prof. Ian Pavord, UK

10:00 The Debate: All Patients with Cough Need Allergy Testing

Dr. Shuayb Elkhalifa, UAE
Dr. Said Isse, UAE

10:30 Coffee Break

Session 2: Inborn Errors of Immunity Moderators: Prof. Suleiman Al-Hammadi & Prof. Gehad Elghazali

10:45 Epidemiology of Inborn Errors of Immunity (IEI) in the MENA Region

Prof. Salem Al Tamemi, Oman

11:05 SCID and New-born Screening

Dr. Hiba Shendi, UAE

11:25 Primary B Cell Deficiency Disease in Adults

Prof. Maryam Al-Nesf Al-Mansouri, Qatar

11:45 New Frontiers in Immunodeficiency

Prof. Ahmed Aziz Bousfiha, Morocco

12:05 Achieving Clinical Remission in Clinical Practice
(Sponsored by AstraZeneca)

Dr. Muhammad Arif, UAE

12:25 Lunch & Prayer

13:30 **Opening Ceremony**

Prof. Mohamed Abuzakouk , UAE

Session 3: Hot Topics in Allergy and Immunology
Moderators: Prof. Rand Arnaout & Dr. Hiba Shendi

13:40	Anaphylaxis: What is New?	Dr. Fadhel Al Sabbagh, Bahrain
14:00	Perioperative Hypersensitivity Assessment	Dr. Fulvio Salvo, UAE
14:20	Oral Manifestations of Immunologic Disorders	Prof. Suhail Al Amad, UAE
14:40	Hyper IgE: Is it Allergy or Immunodeficiency?	Prof. Andrew Gennery, UK
15:00	Type 2 Inflammation: A Common Mechanism for Multiple Inflammatory Diseases <i>(Sponsored by Sanofi)</i>	Prof. Mona AlAhmad, Kuwait

15:20 Coffee Break

Session 4: Urticaria and Angioedema
Moderators: Dr. Iman Nasr & Dr. Hussain Hattawi

15:35	The Latest in Mast Cell Activation Syndromes	Prof. Frank Siebenhaar, Germany
15:55	When to Suspect HAE: Unrecognised Potential Killer	Dr. Shuayb Elkhalifa, UAE
16:15	Advances in HAE Biologicals	Dr. Iman Nasr, Oman
16:35	Unprecedented Outcomes in HAE Management <i>(Sponsored by Takeda)</i>	Dr. Ravi Gutta, UAE
16:55	Living with HAE: Patient Testimonial	Mr. Rashad Matraji, UAE

17:15 Day 1 Adjournment

DAY 2: Sunday, 5 March 2023

7:30 Onsite Registration

Session 5: Allergy and Clinical Immunology for the Practicing Paediatrician and Family Medicine
Moderators: Prof. Salem Al Tamemi, Dr. Abdelay Dabosy & Dr. Hamad Al Hameli

8:30	Eczema and Food Allergy: What is the Relationship?	Dr. Stuart Carr, UAE
8:50	Food Immunotherapy and Early Intervention	Dr. Inmaculada Cerecedo, UAE
9:10	Food Allergy: Intervention Through Intestinal Microbiome	Prof. Amer Azaz, UAE
9:30	Myths About Cow's Milk Allergy	Dr. Hamad Al Hameli, UAE
9:50	Allergy Testing: The Good, The Bad and The Ugly	Prof. Fares Zaitoun, UAE
10:10	Beyond the Symptoms: Targeting the Cause of Allergic Rhinitis with Dust Mite SLIT Tablets <i>(Sponsored by Biologix)</i>	Dr. Stuart Carr, UAE

10:30 Coffee Break

Session 6: Research and Innovation
Moderators: Prof. Elhadi Aburawi & Prof. Mohamed Abuzakouk
Panelists: Prof. Rand Arnaout, Prof. Suleiman Al-Hammadi & Dr. Fulvio Salvo

10:45	Recent Advances in the Mechanism of Anaphylactic Shock	Prof. Abdelouahab Bellou, China
11:05	A Transformational Approach to Managing Fel d1, the Major Cat Allergen <i>(Sponsored by Purina Proplan)</i>	Ms. Lisa Timoner, UAE
11:15	Chronic Inducible Urticaria Plus Spontaneous or Another Inducible Urticaria: Impact of Disease Course, Activity, and Control	Dr. Melba Muñoz Roldán, Germany
11:25	Clinical Characteristics of 39 Moroccan Patients with Chronic Granulomatous Disease	Ms. Assma Dably, Morocco
11:35	Audit of Pediatric Anaphylaxis Management: A Review of Real-Life Management Compared to Best Practice	Dr. Noora Aljasmí, UAE
11:45	Dupilumab Suppresses Type 2 Biomarkers of Inflammation In Patients With Eosinophilic Esophagitis: Results From Part B Of LIBERTY-EoE-TREET	Ms. Monica Fahmy, UAE
11:55	CRUSE – What the First 100 Days Have Taught Us	Dr. Sophia Neisinger, Germany
12:05	Genetic Diagnosis of Inborn Errors of Immunity in an Emerging Country: A Retrospective Study Of 216 Moroccan Patients	Prof. Abderrahmane Moundir, Morocco
12:15	The Role of TSLP in Severe Asthma Management <i>(Sponsored by Astrazeneca)</i>	Dr. Abdulbaset Elkkari, UAE
12:35	Lunch	

Session 7: Hot Topics in Dermatology for Immunologists and Allergists
Moderators: Dr. Muna AlMurráwi, Dr. Mariam Al Suwaidi & Prof. Ahmed Al Dhaheerí

13:45	CSU Management from Theory to Practice <i>(Sponsored by Novartis)</i>	Dr. Meera AlAdawi, UAE
14:05	Skin Manifestations of Immunologic Disorders	Dr. Raghda AlMaashari, UAE
14:25	Biologics in Psoriasis; What Is New?	Dr. Fatima AlBreiki, UAE
14:45	Evaluation and Management of Chronic Pruritus	Dr. Muna AlMurráwi, UAE
15:05	Challenges and Treatment Options in Atopic Dermatitis	Dr. Meera AlAdawi, UAE
15:25	End of Meeting and Closing Remarks	

SPONSORS

DIAMOND SPONSORS



Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development.

Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105,000 people of more than 140 nationalities work at Novartis around the world. For more information visit:

www.novartis.com



GSK is a science-led global healthcare company on a mission to research, develop, manufacture and market innovative medicines and vaccines to unite science, technology and talent to get ahead of disease together.

GSK has a 300-year global legacy, and for more than 65 years has been operating, employing and investing in the Gulf Cooperation Council region.

We aim to positively impact the health of 2.5 billion people over the next 10 years. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

www.gsk.com

SPONSORS

DIAMOND SPONSORS



We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives.

Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients.

We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world's poorest countries. www.sanofi.com



We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally. We have three priorities designed to deliver our growth through innovation strategy.

Accelerate Innovative Science:

Accelerating the next wave of new molecular entities, building our capabilities in immunology and rare diseases, pursuing new scientific modalities and driving R&D productivity

Deliver Growth and Therapy Area Leadership:

Meeting our growth and profitability goals through successful innovation and commercial excellence, as well as completing the Alexion acquisition

Be a Great Place to Work:

Contributing to the enterprise and to society, with a focus on inclusion and diversity, lifelong learning, improving access to healthcare, environmental protection, and ethics and transparency, as well as delivering our Ambition Zero Carbon program.

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.

We are committed to operating in a way that recognizes the interconnection between business growth, the needs of society and the limitations of our planet.

www.astrazeneca.com

SPONSORS

PLATINUM SPONSORS



Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries.

www.takeda.com



Biologix helps multinational pharmaceutical manufacturers bring innovative drugs to market in the Middle East / North Africa (MENA) region. Positioned across 17+ key strategic locations in the Gulf Cooperation Council (GCC), Egypt, North Africa and the Levant, we are pioneers in regional distribution and promotion of innovative products and solutions for difficult-to-treat diseases.

A privately owned pharmaceutical company organized under the laws of the United Arab Emirates (UAE), Biologix provides end-to-end solutions from the preregistration phase all the way to commercial-scale market access and risk management.

Incorporated in the Dubai Airport Free Zone in September 2002, Biologix traces its history back to 1997. We were among the first organizations to recognize the need for long-term strategic partnerships in the MENA region, and today we connect pharma leaders around the world with integrated direct-access healthcare approaches.

www.biologixpharma.com

GOLD SPONSOR



NewBridge Pharmaceuticals, headquartered in Dubai, UAE, is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize U.S. FDA or EMA approved innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.

www.nbpharma.com

SPONSORS

SILVER SPONSORS



Purina Pro Plan is the most advanced nutrition for your pet's best life. That's why we are proud to offer a full spectrum of performance and specialized nutrition formulas, including options that supports healthy ageing, provide guaranteed live probiotics and more. Our innovative nutrition is powered by a team of 500+ nutritionists, veterinarians and scientists.

At Purina Pro Plan, we will never stop researching and enhancing the food your pets depends on every day.

Make sure to pass by our booth to get the opportunity to know more about a novel nutritional approach that can help neutralize the major cat allergen (Fel d 1) in cats' saliva, before it spreads to the environment.

www.purina-arabia.com



HVD Life Sciences is a marketing and distribution company that specializes in sourcing, supplying and supporting life science solutions. We bring a global perspective to our business worldwide, covering regions including Central and Southeast Europe, the Middle East, Africa, the Commonwealth of Independent States, the Far East and Latin America.

We offer a wide range of high quality products from carefully selected manufacturers of innovative and industry-leading tools and technologies. With all of our suppliers, we focus on building strong relationships that will ensure long-term success for our customers, our partners and ourselves.

HVD Life Sciences is not just a reseller. Our relationships with our customers don't end when we close a sale. At HVD Life Sciences, we all take pride in the expertise we bring to our work. Our customers benefit from local sales and support teams with expert product and application knowledge. We specialize in delivering a streamlined sales process, expert customer support and top quality service. Our comprehensive support and service program is as important to our business as the products we ship.

www.hvdlifesciences.com

SPONSORS

SILVER SPONSORS



We are an international group based in Parma, research-oriented, with over 85 years of experience, present in 30 countries. The Chiesi Group researches, develops and markets innovative drugs in three specific areas: AIR (products and services in the respiratory field, from infants to adults), RARE (innovative solutions and personalized services to improve the quality of life of patients with rare and ultra-rare diseases) and CARE (products and services to support specialist care, personal care and well-being).

Since 2019 we are a certified B Corp, while, in 2018, we changed our legal status to a Benefit Company, realizing the desire to measure our impact on society and the environment, combining the need to generate value for the business to acting as a positive force for the community in which we live.

www.chiesi.com



New Country Healthcare (NCH) was founded in 1978 as Country Pharmacy and evolved to New Country Healthcare in 1990, NCH today is a leader in the healthcare sector, with a rich portfolio that includes over 1500 products manufactured in United States, Canada, Europe, Asia and Middle East.

NCH started with a vision of a healthier community by our Chairman Dr. Ghazi Al Koudsi, a UAE board certified pharmacist and consultant to governing agencies. With hard work and dedication, NCH has not only kept their promise to the community but, has also stayed true to the vision of our chairman who inspires every member of the NCH family to give their best every day.

www.nchme.com

CSL Behring

Driven by Our Promise. It began with a promise. CSL Behring's parent company, CSL, was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We are CSL Behring and we are driven by our promise.

www.cslobehring.com

SPONSORS

SILVER SPONSORS

hikma.

We put better health within reach, every day.

By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities.

Our partners collaborate with us because of our reputation for quality, our strong brand recognition, and our US FDA-inspected manufacturing plants. Organisations we work with know they can rely on us to deliver consistently, in all our markets.

We have always been committed to high standards of ethical conduct. In our business and in our dealings with other people. At the heart of this are our three values: Innovation. Caring. Collaboration. These shape the way our people think, work and behave. And ensure the sustainability of our company. In 2017, we achieved the highest ranking of any pharmaceutical company in the UK's Institute of Directors' Good Governance Report.

www.hikma.com



BABIRUS Group is committed to working with healthcare partners across the MENA region to deliver innovative and technologically advanced diagnostic solutions that help to improve people's health.

Headquartered in Dubai, UAE, the company is focused on handling a portfolio of leading global healthcare brands and best in class diagnostic products in three key areas: Molecular Diagnostics, Personalised Medicine, and Immuno Diagnostics.

We believe that the key for helping medical specialists to improve patient outcomes is through a continuous program of medical education and trainings as well as offering ongoing scientific support from our highly qualified team.

www.babirus.ae

When it comes to severe eosinophilic asthma, FASENRA[®] is an optimal treatment option.

Aim For ZERO

- At least **75%** had **ZERO exacerbations** annually¹
- During the **integrated analysis period**
- **62.9%** of patients had **ZERO OCS**²

Rapid improvement

- **+239ml** Immediate*FEV₁ improvement and sustained across 2 years³
- **63.2%** Of patients at EOT had been improved ≥ 0.5 units in ACQ-6⁴

Convenient Dosing

- **8 doses** for first year and **6 doses** in maintenance year⁵

ACQ = asthma control questionnaire; EOT = end of treatment; FEV₁ = forced expiratory volume in 1 second; FeNO = fractional exhaled nitric oxide; IgE = immunoglobulin E; OCS = oral corticosteroid.

References: 1. KORNI ET AL. J ALLERGY CLIN IMMUNOL. PRACT DECEMBER 2021

2. Menzies-Gow A, Gurnell M, Heaney LG, et al. Lancet Respir Med. 2022;10(1):47-58.

3. Data on File, REF-59636, AZPLP. 4. Data on File CSR D3250C00018, REF-1102, AZPLP. 5. FASENRA[®], Summary of Product Characteristics.

AstraZeneca 

UAE
AstraZeneca FZ LLC Gulf P.O. Box: 505070 Dubai, UAE;
Dubai Healthcare City, Building 27, Block D 2nd Floor,
Tel: +971(4)362 4888, Fax: +971(4)362 4898/9

**For Reporting Adverse events and/or Product Quality
Complaints:** <https://contactazmedical.astrazeneca.com>
E-mail: PatientSafety.usgulf@astrazeneca.com
Call AstraZeneca FZ LLC land line: +97143624888.

For Medical Information Enquiries:
Website: <https://contactazmedical.astrazeneca.com>
E-mail: gulf-medicalinfo@astrazeneca.com
Call AstraZeneca FZ LLC land line: +97143624888


KSA
Al-Nakhla Tower - Floor 13th, Ath Thumamah Road
Al Sahafa District, 7198 Unit No. 20, Riyadh 13315 - 3642,
Tel: +966 (011) 22 492 00, Fax: +966 (011) 22 492 91

For Adverse events reporting send email to:
ksa.ae@astrazeneca.com

For Medical info send email to:
medinfo-ksa@astrazeneca.com

IN THE CRIME OF SEVERE ASTHMA INFLAMMATION...

“TSLP MADE US DO IT.”



Thymic stromal lymphopoietin (TSLP), an epithelial cytokine, can be a real mastermind behind inflammation, giving orders for downstream effector cells to follow.^{1,2}

IgE, immunoglobulin E.

References: 1. Corren J. *J Allergy Clin Immunol Pract.* 2019;7(5):1394-1403. 2. Ziegler F, Artis D. Sensing the outside world: TSLP regulates barrier immunity. *Nat Immunol.* 2010;11(4):289-293.

©2023 AstraZeneca. All rights reserved. PromoMats ID: Z5-6698

AstraZeneca 

UAE
AstraZeneca F2 LLC, Gulf P.O. Box 310570 Dubai, UAE
D-Box Healthcare City, Building 22, Block D 2nd Floor.
Tel: +9714413624888, Fax: +971443624888/9
For Reporting Adverse events and/or Product Quality
Complaints: <https://contactus.medical.astrazeneca.com>
E-mail: patient_safety.ap@astrazeneca.com
Call AstraZeneca F2 LLC land line: +97143624888.
For Medical Information Enquiries:
Website: <http://ps/contactus.medical.astrazeneca.com>
E-mail: gulf_medinfo@astrazeneca.com
Call AstraZeneca F2 LLC land line: +97143624888

NUCALA
 mepolizumab

**TAKE CONTROL OF
 RECURRENT NASAL
 POLYPS WITH
 NUCALA¹**

BATTLE TESTED
 IN EOSINOPHILIC DISEASES

**PROVEN RESULTS ACROSS FOUR
 INDICATIONS, INCLUDING CRSWP –
 OUR TRACK RECORD STANDS OUT.²**

For more information, please visit the website for information on eosinophilic diseases at www.nucalacare.com.
 In the United States, mepolizumab is indicated for the treatment of CRSWP in patients 12 years of age and older. For information on the use of NUCALA in patients 12 years of age and older, please visit www.nucalacare.com.
 ©2023 GSK. All rights reserved. NUCALA is a trademark of GSK. Track record stands out.

References:
 1. Villanueva C, Vignola C, Canonica GW, et al. Efficacy and safety of mepolizumab in patients with eosinophilic rhinosinusitis with nasal polyps: a randomized, controlled, phase 3 trial. *Ann Intern Med*. 2019;171(8):502-511.
 2. Johnston AB, Dhaliwal SS, Sporn SA, et al. Efficacy and safety of mepolizumab in patients with eosinophilic asthma: a randomized, controlled, phase 3 trial. *Lancet Respiratory Medicine*. 2015;3(8):583-592.
 ©2023 GSK. All rights reserved. NUCALA is a trademark of GSK. Track record stands out.

GSK



TAKE CONTROL OF RECURRENT NASAL POLYPS WITH NUCALA¹



THE ONLY
ANTI-IL-5 APPROVED FOR NASAL POLYPS²



THE ONLY
BIOLOGIC EXCLUSIVELY STUDIED IN PATIENTS WITH ≥1 PREVIOUS NASAL SURGERY^{1,3-5}

- Over 5x reduction in nasal obstruction VAS score vs. placebo.¹
- 69% reduction in need for surgery vs. placebo in patients with ≥300 eosinophils/ μL .⁸
- 73% of patients experienced improvement in HRQoL.¹



THE ONLY
ONCE-MONTHLY TARGETED THERAPY²

Simple, flexible administration either at home or in office.²



THE ONLY
ONCE-MONTHLY BIOLOGIC APPROVED ACROSS FOUR EOSINOPHILIC DISEASES: SEA, CRSWNP, EGPA AND HES²

CRSWNP: Chronic Rhinosinusitis with Nasal Polyps; **EGPA:** Eosinophilic Granulomatosis with Polyangiitis; **HES:** Hypereosinophilic Syndrome; **HRQoL:** Health-Related Quality of Life; **IL-5:** Interleukin 5; **IL-5R α :** Interleukin 5 α Receptor; **SEA:** Severe Eosinophilic Asthma; **VAS:** Visual Analogue Scale.

References:

1. Han S-K, Barboit C, Fokkens WJ, Durrans M, Wagenvoort M, Lee S-E, Terribi S-G, Morin N, Mouni K, Varney S, W, Sousa A R, Chen B, Higgins C, & SYNAPSE study investigators (2021). Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled phase 3 trial. *The Lancet Respiratory Medicine*, 9(10), pp 1141-1153. 2. Nucala® Summary of Product Characteristics, April 2022. 3. Buchart C, Han J-E, Demossier M, Conster P, Haffner L, Higgins L, Twardy J, H. Barbas P, Cohen D, Finkbein C, Martin D, J, Ditt N, H, Riccardo S, Koenigs J, J, Hara M, & Watanabe Y (2022). Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps in randomized placebo-controlled trial. *The Journal of allergy and clinical immunology*, 149(4), pp 1099-1117. 4. Conster P, Onuchi T, A. Cohen J, Misko J, Hara J, Lee S-E, Koshman M, Liguero-Solis M, Howard M, Zhu A, Chen R, Wang L, Wang L, & Buchart C (2020). Efficacy and safety of oral mepolizumab in nasal polyps: a randomized phase 3 trial. *The Journal of allergy and clinical immunology*, 145(5), pp 994-1005. 5. Barboit C, Han J-E, Demossier M, Haffner L, Cohen J, S, Bousquet J, V, LaBasse T, M, Caron A, J, Shapiro G, P, Hawker C, Olin M, Carreira G, W, Pappas F, Cho S-H, Fokkens W, J, Jaganath S, Zhang M, ... Mawardi P (2019). Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet (London, England)*, 393(10209), pp 1629-1639. 6. Barboit C, Sousa A R, Han J-E, Demossier M, J, Koenigs J, J, Higgins C, Mawardi P, F, Smith S, G, Gentry G, Barak-Ehrenth D E, Hayes A, Chen R, H, Varney S W, & Chatur A R (2022). Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. *The Journal of allergy and clinical immunology*, 149(5), pp 1711-1721. 7.

Choose ACARIZAX® Sooner

Convenient for patients

Delivered by fast-dissolving freeze-dried technology, suitable for at-home treatment^{1,3}

Superior Efficacy

As an add-on to symptom relieving medication^{1,2}

Evidence-Based Treatment

Pioneering and robust clinical evidence in both HDM* allergic asthma and allergic rhinitis^{1,2}

ACARIZAX® is the first and only FDA-approved sublingual tablet for house dust mite – induced allergic rhinitis, with or without conjunctivitis¹

Offer Your Patients
The Pioneering
And Proven
Treatment For
House Dust Mite
Respiratory Allergy

ALK

Biologic

ACARIZAX®

Sublingual Allergen Extract Tablets for House Dust Mite

Redefine control in HDM allergies

Welcome home

¹ Trade name in US is ODACTRA®


² vs. placebo. All patients had no adverse events. Refer to full prescribing information.

³ Zyrtec® fast dissolve tablet technology developed by Catalent Pharms Solutions, Inc. 9

©2014 ALK, Inc. All rights reserved. ALK-14-0016

ALK is a trademark of ALK, Inc. All other trademarks are the property of their respective owners.

¹ Concomitant Zyrtec® fast dissolve tablet technology. Refer to full prescribing information for Zyrtec® fast dissolve tablet. Last accessed July 2014.



BiologiX

PIONEERING.LEADING.ENGAGING

**Bringing innovative products & solutions
for difficult-to-treat diseases
in the MENA region**

Dubai Science Park | Laboratory Complex | Unit 221
P.O.Box: 54405 United Arab Emirates | UAE
+971 4 299 7171 | www.biologixpharma.com



Not an actual patient.

REIMAGINE THE WAY YOU TREAT HAE

Your guide to helping prevent attacks with
the ready-to-use TAKHZYRO prefilled syringe¹

TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.¹


Reference: 1. Takhzyro summary of product characteristics. Takeda Pharmaceuticals, September 2021.



C-APROM/AE/TAKH/0010
Expiry date: Feb. 2025

TAKHZYRO[®]
lanadelumab subcutaneous injection
RETHINK PREVENTION

EXHIBITION FLOOR PLAN



BOOTH NO. COMPANY

1	Novartis
2	Takeda
3	Biologix
4	Hikma.
5	NewBridge Pharma
6	GAACI
7	New Country Healthcare

BOOTH NO. COMPANY

8	GSK
9	Nestle Purina Pro Plan
10	Babirus Medical Equipment
11	CSL Behring
12	HDV Life Sciences
13	Astrazeneca
14	Sanofi

EVENT CALENDAR



THE 9TH ANNUAL ELITE PED-GI CONGRESS 2023



May 4-6, 2023 | BEACH ROTANA HOTEL, ABU DHABI, UAE



Dr. Mohamad Miqdady
Conference Chairman
Chief, Pediatric Gastroenterology, SKMC
Clinical Professor, Khalifa University
Abu Dhabi, UAE

SCIENTIFIC PARTNER



MANAGED BY:



2ND International Paediatric Neurodisability & Neurorehabilitation Conference



MAY 26 - 28, 2023
ABU DHABI, UNITED ARAB EMIRATES



Dr. Tarek Ibrahim El-Azzabi
Conference Chairman
MBBCh, MRCPCh, FRCPCh, DCh, CCT (UK)
Senior Consultant Paediatrician - Neurodisability
Sheikh Khalifa Medical City, Abu Dhabi
A/Assistant Professor in Paediatric, UAE University
Al Ain, UAE

SAVE THE DATE

SCIENTIFIC PARTNER



THE ROYAL
SOCIETY OF
MEDICINE

MANAGED BY:



EVENT CALENDAR

CADAVER WORKSHOP
HIP, KNEE & SHOULDER JOINT
INTERVENTIONAL PAIN MANAGEMENT

18 - 19 March 2023 | Venue: Gulf Medical University, Ajman, UAE

Dr. Amar Saiti
Course Director
Consultant Anesthesia and
Interventional Pain Medicine
Ajman, UAE

SCIENTIFIC PARTNER
MANAGED BY
PEARL
EVENT MANAGEMENT SERVICES

March 18 - 19, 2023
Gulf Medical University, Ajman, UAE

INTERVENTIONAL PAIN MANAGEMENT CADAVER WORKSHOP
SPECIAL FOCUS - HEADACHE,
FACIAL PAIN, CANCER PAIN,
MSK & SPINE INTERVENTIONS

6 - 7 May 2023 | Venue: Gulf Medical University, Ajman, UAE

Dr. Amar Saiti
Course Director
Consultant Anesthesia and
Interventional Pain Medicine
Ajman, UAE

SCIENTIFIC PARTNER
MANAGED BY
PEARL
EVENT MANAGEMENT SERVICES

May 6 - 7, 2023
Gulf Medical University, Ajman, UAE

CADAVER WORKSHOP
SPINAL PAIN MANAGEMENT,
NEUROMODULATION IN PAIN MANAGEMENT
& SPASTICITY WORKSHOP

17 - 18 June 2023 | Venue: Gulf Medical University, Ajman, UAE

Dr. Amar Saiti
Course Director
Consultant Anesthesia and
Interventional Pain Medicine
Ajman, UAE

SCIENTIFIC PARTNER
MANAGED BY
PEARL
EVENT MANAGEMENT SERVICES

June 17 - 18, 2023
Gulf Medical University, Ajman, UAE

NYSORA
8th NYSORA International Symposium:
Advances in Regional Anesthesia,
Pain and Perioperative Medicine

10 - 12 November 2023 | Two Seasons Hotel, Dubai, UAE

AMAR SAITI, MD.
Course Director, Anesthesia and Pain Medicine
Ajman, UAE

ADMIR HEDIC, MD, PhD.
Professor of Anesthesiology
Associate NYSORA (8th) International Conference Co-Chairman
Chairman, NYSORA (8th) International Conference Regional Anesthesia,
Pain and Perioperative Medicine
Ajman, UAE

SCIENTIFIC PARTNER
MANAGED BY
PEARL
EVENT MANAGEMENT SERVICES

November 10 - 12, 2023
Two Seasons Hotel, Dubai, UAE

SAVE THE DATE

The ART of Neonatal Care
— Neonatal Service Committee —

17 - 18 NOVEMBER 2023 | TWO SEASONS HOTEL, DUBAI, UAE

Dr. Mona Al Aleeli
Conference Chairman
Consultant Pediatrician and Neonatologist
Head of Neonatology Department
Al Qassimi Women's and Children's Hospital, Sharjah
Head of Neonatal Service Committee - EHS

SCIENTIFIC PARTNER
MANAGED BY
PEARL
EVENT MANAGEMENT SERVICES

HOW TO GET CME

Easy steps to receive your CME Certificate!

1. Visit our website, www.pems.me and click the **CME Certificate Tab**
2. Select the event that you have attended and complete the evaluation form.
3. The CME specialist will review the evaluation form and your attendance.
4. If your attendance is confirmed, you will receive your CME certificate within 24-48 hours.

NOTE: In case you did not receive your CME certificate, please send email to admin@pems.me or **Whatsapp message to: +971 56 435 1553**

MANAGED BY:



 www.pems.me

 +971 58 584 4985

 info@pems.me

 Business Center, Al Shmookh Building,
UAQ Free Trade Zone, Umm Al Quwain,
United Arab Emirates

 Pearl Event Management Services

 @pearleventsuae

 @pearleventsuae

 Pearl Event Management Services

 Pearl Event Management Services